Uwe Haberkorn
Nuclear medicine physician whose group invented FAPI PET tracers and pioneered PSMA and FAP radioligand therapy.
Overview
Uwe Haberkorn is Head of Nuclear Medicine at Heidelberg University Hospital and the German Cancer Research Center (DKFZ). His specialisms are nuclear medicine, FAP-targeted radiopharmaceuticals and theranostics, with a focus on the FAP and PSMA targets. His Heidelberg group invented the quinoline-based FAP inhibitor (FAPI) tracers, and his Journal of Nuclear Medicine paper reported 68Ga-FAPI PET/CT tracer uptake across 28 different kinds of cancer. The group also led early PSMA-617 and FAP-targeted radioligand therapy in humans, and his record links him to FAP-2286 and lutetium-177 vipivotide tetraxetan. His publications are listed on PubMed.
| Title | Journal | Year |
|---|---|---|
| 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer | Journal of Nuclear Medicine | 2019 |
Similar pages
not linked directly; found by shared links- PersonClemens Kratochwil
Shares 177Lu-PSMA-617 then 225Ac-PSMA rescue therapy, 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer, Journal of Nuclear Medicine, Heidelberg University Hospital / NCT / DKFZ.
- PersonFrederik Giesel
Shares Journal of Nuclear Medicine, Heidelberg University Hospital / NCT / DKFZ, A university cyclotron network with shared regulatory files for new tracers, European Association of Nuclear Medicine.
- InstitutionUniversity Hospital Düsseldorf / CIO Düsseldorf
Shares Heidelberg University Hospital / NCT / DKFZ, FAP-2286 (177Lu / 68Ga), FAP, FAPI PET.
- IdeaFAP theranostics as a pan-cancer stromal strategy
Shares A university cyclotron network with shared regulatory files for new tracers, FAP-2286 (177Lu / 68Ga), FAP, FAPI PET.
- PersonKen Herrmann
Shares European Association of Nuclear Medicine, FAP, FAPI PET, PSMA.
- IdeaFAP-targeted radioligand therapy for sarcoma
Shares FAP-2286 (177Lu / 68Ga), FAP, FAPI PET, Gallium-68.
- PersonJeremie Calais
Shares Journal of Nuclear Medicine, PSMA, PSMA PET, Gallium-68.
- PersonMichael Hofman
Shares A university cyclotron network with shared regulatory files for new tracers, PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha, PSMA, Lutetium-177 vipivotide tetraxetan.